Doxorubicin

Warnings & Precautions

Doxorubicin is a potent cytotoxic chemotherapy agent that requires careful handling, strict administration protocols, and close patient monitoring due to its narrow safety margin and potential for severe toxicity.

• Contraindications: Do not use in patients with hypersensitivity to anthracyclines, pre-existing myelosuppression, impaired cardiac function, or those that have reached the maximum cumulative lifetime dose.
• Renal disease (cats): Contraindicated in cats with pre-existing renal insufficiency due to risk of nephrotoxicity.
• Hepatic impairment: Use with caution; dose reductions are required in patients with significant liver dysfunction.
• Cardiac risk: Monitor cardiac function carefully, especially in breeds predisposed to dilated cardiomyopathy (e.g., Dobermans, Boxers); risk increases with cumulative dosing.
• MDR1 mutation (dogs): Dogs with MDR1 (ABCB1) mutation may have increased risk of toxicity; dose reduction or avoidance may be required.
• Extravasation risk: Accidental perivascular administration can cause severe tissue necrosis; ensure proper IV catheter placement and monitor continuously during infusion.
• Administration technique: Must be given slowly IV (over at least 10–15 minutes) in a free-flowing line; avoid SC or IM administration.
• Hazardous drug handling: Classified as a hazardous drug (NIOSH); use appropriate personal protective equipment during preparation and administration.
• Post-treatment precautions: Drug residues may be present in urine and feces for several days; appropriate handling precautions should be followed.
• Drug confusion risk: Do not confuse doxorubicin with similarly named drugs (e.g., doxapram) or liposomal formulations.

Drug Interactions

Doxorubicin may interact with multiple drugs, primarily through additive toxicity, altered metabolism, or increased exposure. Careful monitoring and dose adjustments may be required when used in combination with the following medications.

• Calcium channel blockers (e.g., diltiazem, verapamil): May increase the risk of cardiotoxicity when used with doxorubicin.
• Cisplatin: Increased risk of toxicity, particularly myelosuppression.
• Cyclophosphamide: May increase doxorubicin concentrations and prolong hematologic toxicity.
• Cyclosporine: Increases doxorubicin and active metabolite concentrations; concurrent use should be avoided.
• Ketoconazole: May increase doxorubicin levels and risk of toxicity; avoid concurrent use.
• Leflunomide: May result in additive hematologic toxicity.
• Phenobarbital: May increase elimination and reduce doxorubicin concentrations.
• Quinidine: May increase doxorubicin exposure.
• Spinosad: May increase doxorubicin and metabolite concentrations, increasing toxicity risk.
• Streptozocin: May inhibit doxorubicin metabolism.
• Vaccines (live or modified-live): Increased risk of infection in immunocompromised patients.
• Warfarin: Increased risk of bleeding.
• Zidovudine: Increased risk of neutropenia.
• Morphine: May increase morphine exposure when used concurrently.
• Glucosamine: May reduce doxorubicin effectiveness.

Side Effects & Overdose

Side Effects

Adverse effects of doxorubicin are common and primarily related to its cytotoxic effects on rapidly dividing cells. Severity may vary depending on dose, protocol, and individual patient sensitivity.

• Myelosuppression: Dose-limiting toxicity; neutrophil and platelet nadirs typically occur 7–10 days after administration.
• Gastrointestinal toxicity: Vomiting and nausea commonly occur within 72 hours; diarrhea may develop several days later.
• Cardiotoxicity (dogs): May be acute (arrhythmias during or shortly after infusion) or cumulative, leading to dilated cardiomyopathy and congestive heart failure.
• Nephrotoxicity (cats): Renal injury may occur; monitoring of renal parameters is required.
• Hypersensitivity reactions: Acute reactions (especially in dogs) may include urticaria, facial swelling, vomiting, hypotension, and arrhythmias.
• Alopecia: May be generalized or localized; dogs may lose whiskers, and cats may lose whiskers and guard hairs.
• Stomatitis: Oral mucosal irritation may occur.
• Extravasation injury: Severe tissue necrosis and ulceration may occur if the drug leaks outside the vein.

Overdose

Acute overdose of doxorubicin may result in severe exacerbation of its toxic effects. There is no specific antidote, and management is primarily supportive.

• Severe myelosuppression: Increased risk of infection, bleeding, and bone marrow failure.
• Gastrointestinal toxicity: Severe vomiting, diarrhea, and mucosal damage may occur.
• Cardiotoxic effects: Increased risk of arrhythmias and cardiac dysfunction.
• Supportive care: Includes antiemetics, fluid therapy, gastrointestinal protectants, and monitoring.
• Hematologic support: Broad-spectrum antimicrobials and colony-stimulating factors (e.g., filgrastim) may be required in severe cases.
• Consultation: Veterinary toxicology consultation is recommended in suspected overdose cases.

Key Notes

Practical clinical points that support safe and effective use of doxorubicin in dogs and cats:

• Widely used cornerstone drug: Considered one of the most effective and commonly used chemotherapeutic agents in veterinary oncology protocols.
• Cell cycle–nonspecific activity: Acts on both dividing and non-dividing cells, contributing to its broad antitumor efficacy.
• Triphasic elimination: Exhibits a multi-phase elimination pattern due to extensive tissue binding and slow release from tissues.
• Biliary excretion predominance: Primarily eliminated via bile and feces, with minimal renal excretion.
• High tissue binding: Extensive binding to tissues contributes to prolonged drug persistence in the body.
• Does not cross CSF effectively: Limited penetration into the central nervous system, which may affect efficacy in CNS tumors.
• Residue persistence: Drug residues may remain detectable in urine and feces for several days after administration.